Clinical Trials Logo
  1. Home
  2. Scleroderma, Diffuse
  3. NCT05148598

ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma — STAR-II  

Scleroderma, Diffuse Clinical Trial

Official title:
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells - A Randomized, Double-Blind, Placebo-Controlled Study - The STAR-II Trial

Clinical Trial Summary

The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.

Clinical Trial Description

The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05148598
Study type Interventional
Source Paracrine, INC.
Contact
Status Not yet recruiting
Phase Phase 3
Start date February 28, 2023
Completion date December 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Completed NCT02503644 - Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis Phase 2
Completed NCT05622578 - Phenotyping of Chronic Pain in Diffused Systemic Scleroderma N/A
Terminated NCT02374320 - Exparel as a Nerve Block for Severe Hand Pain Phase 2/Phase 3
Completed NCT00442611 - A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Phase 1/Phase 2
Not yet recruiting NCT05351060 - Novel Splinting Technique Using 3D Models N/A
Completed NCT04647890 - Effects of FT011 in Systemic Sclerosis Phase 2
Recruiting NCT02682511 - Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Phase 2
Recruiting NCT00428883 - High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis Phase 2/Phase 3
Active, not recruiting NCT03831438 - Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis Phase 1
Terminated NCT04837131 - A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Phase 2
Recruiting NCT01347008 - Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Phase 3